Cart
0

ASEAN and China Biosimilars Market by Molecule Type (Human Growth Hormone, Erythropoietin, Monoclonal Antibody, Insulin, Interferon, Granulocyte-Colony Stimulating Factor, and Peptide), and Application (Blood Disorder, Oncology Disease, Chronic & Autoimmune Disease, Growth Hormone Deficiency, and Others): Opportunity Analysis and Industry Forecast, 2017 - 2025

Get 20% Free Customization In This Report
LI_185080
Pages: 130
Nov 2018 | 285 Views
 
Author's : Tanvi Sapatnekar, Suraj Sajeev
Tables: 52
Charts: 33
 

ASEAN and China Biosimilars Market Overview:

The ASEAN and China biosimilars market was valued at $687.6 million in 2017 and is expected to reach $5,506.2 million by 2025 with a CAGR of 29.7% during the forecast period. Biologics experiences rapid growth in the pharmaceutical industry that fuels the development of new treatments for life-threatening and rare illnesses. However, expiry of patents of the biologics that incorporate recombinant technology has been on the rise in recent years. Thus, research-based and generic pharmaceutical companies are pursuing the opportunity to develop "generic" substitutes for original biologics that are known as biosimilars.

The ASEAN and China biosimilars market is segmented into molecule type, application, and region. Based on molecule type, the market is divided into human growth hormone, erythropoietin, monoclonal antibodies, insulin, interferon, granulocyte-colony stimulating factor, and peptide. Based on application, the market is classified into blood disorders, oncology diseases, chronic and autoimmune diseases, growth hormone deficiency, and others. Further, the chronic and autoimmune diseases segment is sub-categorized into diabetes, rheumatoid arthritis (RA), glaucoma, and others. Based on region, the market is analyzed across China and ASEAN region.

The key driving factors of the ASEAN and China biosimilars market include rise in the number of blockbuster drugs whose patents would be expiring along with high prevalence of chronic diseases among the ageing population across the ASEAN countries and China. In addition, lower cost of biosimilars drugs than original biologics has fueled the market growth. However, high initial investment in R&D is anticipated to hamper the growth of the market. Moreover, increased focus of the international key players to invest in untapped economies of the ASEAN region and China offers lucrative opportunities for expansion of the biosimilars market.

Get more information on this report: Request Sample Pages

Molecule Type segment review

ASEAN and China biosimilars market comprises seven molecule types, namely, human growth hormone, erythropoietin, monoclonal antibody, insulin, interferon, granulocyte-colony stimulating factor, and peptide. The monoclonal antibody segment generated the highest revenue in 2017 and is anticipated to maintain its dominance throughout the forecast period. This is attributed to the diverse diagnostic applications of the monoclonal antibodies (mAbs) technology in the healthcare industry. In addition, mAbs are increasingly applied in the development of novel treatment options for cancer, infectious, cardiovascular, and inflammatory diseases. The human growth hormone segment is anticipated to grow at a rapid pace from 2018 to 2025 in the ASEAN and China biosimilars market. Increase in the development of new treatment plans that involve shift from originator to biosimilar human growth hormone across the ASEAN countries and China has contributed to the robust growth of the segment.

Get more information on this report: Request Sample Pages

Application segment review

ASEAN and China biosimilars market constitutes five applications, namely, blood disorders, oncology diseases, chronic and autoimmune diseases, growth hormone deficiency, and others. The chronic and autoimmune diseases segment is further categorized into rheumatoid arthritis (RA), diabetes, glaucoma, and others. The oncology diseases segment generated the highest revenue in 2017 and is anticipated to remain dominant throughout the forecast period. This is attributed to rise in healthcare expenditures owing to expensive drugs used in the treatment of cancer. This has propelled the pharmaceutical manufacturers to invest in the production of cheaper alternatives, i.e. biosimilars. However, the chronic and autoimmune diseases segment is anticipated to grow at the fastest pace during 2018-2025 in the ASEAN and China biosimilars market.

Significant increase in the preference for biosimilars such as human growth hormone and monoclonal antibodies, over branded biologics across the ASEAN countries and China has contributed to the growth of the segment. Increase in the prevalence of glaucoma and diabetes across ASEAN countries and China significantly contributed to the highest CAGR of this segment.

The major companies profiled in the report include 3SBIO Inc., Qilu Pharmaceutical, Novartis International AG (Sandoz International GmBH), Pfizer Inc. (Hospira), STADA Arzneimittel, Beijing SL Pharmaceutical Co., Ltd., Fosun Pharmaceutical (Shanghai Fosun Pharmaceutical Co., Ltd.), Amgen Inc., AstraZeneca Plc, and Teva Pharmaceutical Industries Ltd.

Key Benefits ASEAN and China Biosimilars Market:

  • The study provides an in-depth analysis along with the current trends and future estimations of the ASEAN and China biosimilars market to elucidate the imminent investment pockets.

  • A comprehensive analysis of the factors that drive and restrict the market growth is provided.

  • The quantitative analysis of the industry from 2017 to 2025 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.

  • An extensive analysis of the key segments of the industry is provided to understand the molecule type and applications of biosimilars across ASEAN countries and China.

  • The key players and their strategies are analyzed to understand the competitive outlook of the market.

ASEAN and China Biosimilars Key Market Segments:

By Molecule Type

  • Human Growth Hormone

  • Erythropoietin

  • Monoclonal Antibody

  • Insulin

  • Interferon

  • Granulocyte-Colony Stimulating Factor

  • Peptide

By Application

  • Blood Disorders

  • Oncology Diseases

  • Chronic and Autoimmune Diseases

    • Rheumatoid Arthritis (RA)

    • Diabetes

    • Glaucoma

    • Others

  • Growth Hormone Deficiency

  • Others

By Region

  • China

  • ASEAN Region

    • Singapore

    • Malaysia

    • Thailand

    • Indonesia

    • Philippines

    • Vietnam

    • Rest of ASEAN Countries

 

Chapter: 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. key market segments
1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2: EXECUTIVE SUMMARY

2.1. CXO perspective

Chapter: 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top Winning Strategies

3.3. Porters five forces analysis
3.4. Asean biosimilars market size and forecast
3.5. China biosimilars market size and forecast
3.6. Market dynamics

3.6.1. Drivers

3.6.1.1. Various blockbusters going off patent
3.6.1.2. High prevalence of chronic diseases among ageing population
3.6.1.3. Lower cost of biosimilars drugs than original biologics

3.6.2. Restraints

3.6.2.1. High initial investment in research and development
3.6.2.2. Medical efficacy and patient safety

3.6.3. Opportunity

3.6.3.1. Emergence of bio-better drugs

Chapter: 4: ASEAN AND CHINA BIOSIMILARS MARKET, BY MOLECULE TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Human growth hormone

4.2.1. Key market trends and growth opportunities
4.2.2. Market size and forecast

4.3. Erythropoietin

4.3.1. Key market trends and growth opportunities
4.3.2. Market size and forecast

4.4. Monoclonal antibodies

4.4.1. Key market trends and growth opportunities
4.4.2. Market size and forecast

4.5. Insulin

4.5.1. Key market trends and growth opportunities
4.5.2. Market size and forecast

4.6. Interferon

4.6.1. Key market trends and growth opportunities
4.6.2. Market size and forecast

4.7. Granulocyte-Colony Stimulating Factor

4.7.1. Key market trends and growth opportunities
4.7.2. Market size and forecast

4.8. Peptide

4.8.1. Key market trends and growth opportunities
4.8.2. Market size and forecast

Chapter: 5: ASEAN AND CHINA BIOSIMILARS MARKET, BY APPLICATION

5.1. Overview

5.1.1. Market size and forecast

5.2. Blood Disorders

5.2.1. Market size and forecast

5.3. Oncology Diseases

5.3.1. Market size and forecast

5.4. Chronic and Autoimmune Diseases

5.4.1. Market size and forecast
5.4.2. Rheumatoid Arthritis (RA)

5.4.2.1. Market size and forecast

5.4.3. Diabetes

5.4.3.1. Market size and forecast

5.4.4. Glaucoma

5.4.4.1. Market size and forecast

5.4.5. Others

5.4.5.1. Market size and forecast

5.5. Growth hormone deficiency

5.5.1. Market size and forecast

5.6. Others

5.6.1. Market size and forecast

Chapter: 6: COMPANY PROFILES

6.1. 3SBIO INC.

6.1.1. Company overview
6.1.2. Company snapshot
6.1.3. Operating business segments
6.1.4. Product portfolio
6.1.5. Business performance
6.1.6. Key strategic moves and developments

6.2. Qilu Pharmaceutical

6.2.1. Company overview
6.2.2. Company snapshot
6.2.3. Operating business segments
6.2.4. Product portfolio
6.2.5. Key strategic moves and developments

6.3. Novartis International AG (Sandoz International GmBH)

6.3.1. Company overview
6.3.2. Company snapshot
6.3.3. Operating business segments
6.3.4. Product portfolio
6.3.5. Business performance
6.3.6. Key strategic moves and developments

6.4. Pfizer Inc. (Hospira)

6.4.1. Company overview
6.4.2. Company snapshot
6.4.3. Operating business segments
6.4.4. Product portfolio
6.4.5. Business performance
6.4.6. Key strategic moves and developments

6.5. STADA Arzneimittel

6.5.1. Company overview
6.5.2. Company snapshot
6.5.3. Operating business segments
6.5.4. Product portfolio
6.5.5. Business performance

6.6. Beijing SL Pharmaceutical Co., Ltd.

6.6.1. Company overview
6.6.2. Company snapshot
6.6.3. Operating business segments
6.6.4. Product portfolio

6.7. Fosun Pharmaceutical (Shanghai Fosun Pharmaceutical Co., Ltd.)

6.7.1. Company overview
6.7.2. Company snapshot
6.7.3. Operating business segments
6.7.4. Product portfolio
6.7.5. Business performance
6.7.6. Key strategic moves and developments

6.8. Amgen Inc.

6.8.1. Company overview
6.8.2. Company snapshot
6.8.3. Operating business segments
6.8.4. Product portfolio
6.8.5. Business performance
6.8.6. Key strategic moves and developments

6.9. AstraZeneca Plc

6.9.1. Company overview
6.9.2. Company snapshot
6.9.3. Operating business segments
6.9.4. Product Portfolio
6.9.5. Business performance

6.10. Teva Pharmaceutical Industries Ltd.

6.10.1. Company overview
6.10.2. Company snapshot
6.10.3. Operating business segments
6.10.4. Product portfolio
6.10.5. Business performance

LIST OF TABLES

TABLE 01. ASEAN BIOSIMILARS MARKET, BY COUNTRY, 20172025 ($MILLION)
TABLE 02. OFF GOING PATENTS 2013-2016
TABLE 03. ASEAN BIOSIMILARS MARKET, BY MOLECULE TYPE, 20172025 ($MILLION)
TABLE 04. CHINA BIOSIMILARS MARKET, BY MOLECULE TYPE, 20172025 ($MILLION)
TABLE 05. ASEAN AND CHINA BIOSIMILARS MARKET, BY MOLECULE TYPE, 20172025 ($MILLION)
TABLE 06. BIOSIMILARS MARKET FOR HUMAN GROWTH HORMONE, BY REGION, 20172025 ($MILLION)
TABLE 07. BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY REGION, 20172025 ($MILLION)
TABLE 08. MONOCLONAL ANTIBODIES FROM COMPANEIS IN CHINA
TABLE 09. BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 20172025 ($MILLION)
TABLE 10. PREVALENCE OF DIABETES IN CHINA AND ASEAN COUNTRIES
TABLE 11. BIOSIMILARS MARKET FOR INSULIN, BY REGION, 20172025 ($MILLION)
TABLE 12. BIOSIMILARS MARKET FOR INTERFERON, BY REGION, 20172025 ($MILLION)
TABLE 13. BIOSIMILARS MARKET FOR GRANULOCYTE-COLONY STIMULATING FACTOR, BY REGION, 20172025 ($MILLION)
TABLE 14. BIOSIMILARS MARKET FOR PEPTIDE, BY REGION, 20172025 ($MILLION)
TABLE 15. ASEAN BIOSIMILARS MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 16. CHINA BIOSIMILARS MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 17. ASEAN AND CHINA BIOSIMILARS MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 18. BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY REGION, 20172025 ($MILLION)
TABLE 19. BIOSIMILARS MARKET FOR ONCOLOGY DISEASES, BY REGION, 20172025 ($MILLION)
TABLE 20. BIOSIMILARS MARKET FOR CHRONIC AND AUTOIMMUNE DISEASES, BY REGION, 20172025 ($MILLION)
TABLE 21. BIOSIMILARS MARKET FOR RHEUMATOID ARTHRITIS (RA), BY REGION, 20172025 ($MILLION)
TABLE 22. BIOSIMILARS MARKET FOR DIABETES, BY REGION, 20172025 ($MILLION)
TABLE 23. BIOSIMILARS MARKET FOR GLAUCOMA, BY REGION, 20172025 ($MILLION)
TABLE 24. BIOSIMILARS MARKET FOR OTHERS, BY REGION, 20172025 ($MILLION)
TABLE 25. BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY, BY REGION, 20172025 ($MILLION)
TABLE 26. BIOSIMILARS MARKET FOR OTHERS, BY REGION, 20172025 ($MILLION)
TABLE 27. 3SBIO: COMPANY SNAPSHOT
TABLE 28. 3SBIO: APPLICATION PORTFOLIO
TABLE 29. QILU: COMPANY SNAPSHOT
TABLE 30. SANDOZ: COMPANY SNAPSHOT
TABLE 31. NOVARTIS: OPERATING SEGMENTS
TABLE 32. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 33. PFIZER: COMPANY SNAPSHOT
TABLE 34. PFIZER: OPERATING SEGMENTS
TABLE 35. PFIZER: PRODUCT PORTFOLIO
TABLE 36. STADA: COMPANY SNAPSHOT
TABLE 37. STADA: OPERATING SEGMENTS
TABLE 38. STADA: PRODUCT PORTFOLIO
TABLE 39. BEIJING SL: COMPANY SNAPSHOT
TABLE 40. BEIJING SL: OPERATING SEGMENTS
TABLE 41. BEIJING SL: PRODUCT PORTFOLIO
TABLE 42. FOSUN PHARMACEUTICAL: COMPANY SNAPSHOT
TABLE 43. FOSUN PHARMACEUTICAL: OPERATING SEGMENTS
TABLE 44. FOSUN PHARMACEUTICAL: PIPELINE PRODUCT PORTFOLIO
TABLE 45. AMGEN: COMPANY SNAPSHOT
TABLE 46. AMGEN: PRODUCT PORTFOLIO
TABLE 47. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 48. ASTRAZENECA: OPERATING SEGMENTS
TABLE 49. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 50. TEVA: COMPANY SNAPSHOT
TABLE 51. TEVA: OPERATING SEGMENTS
TABLE 52. TEVA: PIPELINE PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01. ASEAN AND CHINA MARKET SEGMENTATION
FIGURE 02. TOP WINNING STRATEGIES, BY YEAR, 2015-2018*
FIGURE 03. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2015-2018* (%)
FIGURE 04. TOP WINNING STRATEGIES, BY COMPANY, 2015-2018*
FIGURE 05. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 06. MODERATE BARGAINING POWER OF BUYERS
FIGURE 07. LOW THREAT OF SUBSTITUTION
FIGURE 08. MODERATE THREAT OF NEW ENTRANT
FIGURE 09. MODERATE COMPETITIVE RIVALRY
FIGURE 10. ASEAN BIOSIMILARS MARKET, 20172025 ($MILLION)
FIGURE 11. CHINA BIOSIMILARS MARKET, 20172025 ($MILLION)
FIGURE 12. ASEAN AND CHINA BIOSIMILARS MARKET: RESTRAINTS, DRIVERS, AND OPPORTUNITY
FIGURE 13. 3SBIO, 20152017 ($MILLION)
FIGURE 14. NOVARTIS: NET SALES, 20152017 ($MILLION)
FIGURE 15. NOVARTIS: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 16. NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 17. PFIZER: NET SALES, 20152017 ($MILLION)
FIGURE 18. PFIZER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 19. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 20. STADA: NET SALES, 20152017 ($MILLION)
FIGURE 21. STADA: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 22. STADA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 23. FOSUN PHARMACEUTICAL: NET SALES, 20152017 ($MILLION)
FIGURE 24. FOSUN PHARMACEUTICAL: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 25. FOSUN PHARMACEUTICAL: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 26. AMGEN: NET SALES, 20152017 ($MILLION)
FIGURE 27. AMGEN: REVENUE SHARE BY PRODUCT, 2017 (%)
FIGURE 28. AMGEN: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 29. ASTRAZENECA: REVENUE, 20152017 ($MILLION)
FIGURE 30. ASTRAZENECA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 31. TEVA: NET SALES, 20152017 ($MILLION)
FIGURE 32. TEVA: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 33. TEVA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

 

The biosimilars industry is projected to witness paradigm shift in the coming years across ASEAN countries and China. Biosimilars have gained significant momentum in the recent years and are expected to witness this trend in future. In addition, approximately 85 major biologics are anticipated to go off-patent by the end of 2020. Thus, considerable rise in the number of off-patents is expected to create a platform for biosimilar developers and manufacturers. Moreover, insulin and human growth hormone biosimilars serve to be attractive areas for investment in the biosimilars industry. Rise in number of diabetic patients acts as a key contributor to the demand for insulin biosimilars. According to data analysis performed by the Pan African Medical Journal in 2014, approximately 436 million patients are expected to be affected by diabetes by the end of 2030.

Rapid penetration of biosimilars in the management of several chronic diseases along with increase in accessibility of biosimilars drives the growth of the ASEAN and China biosimilars market. Further, increase in number of product approvals exhibited by key players in the market has supplemented the market growth. For instance, Pfizer and Amgen have adopted product approval as their key growth strategy in the recent years.

 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 

Request Sample

Request Customization

Request sample

OR

Purchase Full Report of
ASEAN and China Biosimilars Market

  • Data Pack
  • $2300
  • Restricted to one authorized users
  • One print only
  • Available in Excel
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $3200
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $3844
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprise
    License/PDF

  • $5360
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Access reports on all emerging
market of Life Sciences on Knowledge Tree Platform
Free Demo